Cardiovascular Drugs Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. End Users Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cardiovascular Drugs Market 

5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cardiovascular Drugs Market, By Drug Type

8.1. Cardiovascular Drugs Market, by Drug Type, 2023-2032

8.1.1. Antihypertensive

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Anticoagulants

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Antihyperlipidemic

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Antiplatelet Drugs

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Cardiovascular Drugs Market, By Disease Indication

9.1. Cardiovascular Drugs Market, by Disease Indication, 2023-2032

9.1.1. Hypertension

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Coronary Artery Disease

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Hyperlipidaemia

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Arrhythmia

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Cardiovascular Drugs Market, By Route of Administration

10.1. Cardiovascular Drugs Market, by Route of Administration, 2023-2032

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Parenteral

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Cardiovascular Drugs Market, By Drug Classification

11.1. Cardiovascular Drugs Market, by Drug Classification, 2023-2032

11.1.1. Branded Drugs

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Generic Drugs

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Cardiovascular Drugs Market, By Mode of Purchase

12.1. Cardiovascular Drugs Market, by Mode of Purchase, 2023-2032

12.1.1. Prescription-Based Drugs

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Over-The-Counter Drugs

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Cardiovascular Drugs Market, By End Users

13.1. Cardiovascular Drugs Market, by End Users, 2023-2032

13.1.1. Hospital Pharmacies

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Online Pharmacies

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Retail Pharmacies

13.1.3.1. Market Revenue and Forecast (2020-2032)

13.1.4. Others

13.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global Cardiovascular Drugs Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.1.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.1.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.1.6. Market Revenue and Forecast, by End Users (2020-2032)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.1.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.1.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.7.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.1.8. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.1.8.1. Market Revenue and Forecast, by End Users (2020-2032) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Disease Indication (2020-2032) 

14.1.9.3. Market Revenue and Forecast, by Route of Administration (2020-2032) 

14.1.9.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.1.10. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.1.11. Market Revenue and Forecast, by End Users (2020-2032)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.2.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.4. Market Revenue and Forecast, by Drug Classification (2020-2032) 

14.2.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.2.6. Market Revenue and Forecast, by End Users (2020-2032)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.2.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.9. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.2.10. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.2.10.1. Market Revenue and Forecast, by End Users (2020-2032)

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.2.11.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.12. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.2.13. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.2.14. Market Revenue and Forecast, by End Users (2020-2032)

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.2.15.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.2.15.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.15.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.2.16. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.2.16.1. Market Revenue and Forecast, by End Users (2020-2032)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.2.17.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.2.17.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.17.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.2.18. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.2.18.1. Market Revenue and Forecast, by End Users (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.3.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.3.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.3.6. Market Revenue and Forecast, by End Users (2020-2032)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.3.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.7.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.3.8. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.3.9. Market Revenue and Forecast, by End Users (2020-2032)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.3.10.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.3.11. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.3.11.1. Market Revenue and Forecast, by End Users (2020-2032)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.3.12.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.3.12.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.12.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.3.12.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.3.12.6. Market Revenue and Forecast, by End Users (2020-2032)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.3.13.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.3.13.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.13.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.3.13.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.3.13.6. Market Revenue and Forecast, by End Users (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.4.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.4.6. Market Revenue and Forecast, by End Users (2020-2032)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.4.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.7.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.4.8. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.4.9. Market Revenue and Forecast, by End Users (2020-2032)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.4.10.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.4.11. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.4.12. Market Revenue and Forecast, by End Users (2020-2032)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.4.13.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.4.13.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.13.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.4.13.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.4.13.6. Market Revenue and Forecast, by End Users (2020-2032)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.4.14.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.4.14.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.14.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.4.14.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.4.14.6. Market Revenue and Forecast, by End Users (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.5.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.5.6. Market Revenue and Forecast, by End Users (2020-2032)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.5.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.5.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.7.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.5.8. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.5.8.1. Market Revenue and Forecast, by End Users (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Type (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Disease Indication (2020-2032)

14.5.9.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Drug Classification (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Mode of Purchase (2020-2032)

14.5.9.6. Market Revenue and Forecast, by End Users (2020-2032)

Chapter 15. Company Profiles

15.1. Bristol-Myers Squibb Company

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiative

15.2. Bayer AG

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Pfizer Inc

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Janssen Pharmaceuticals, Inc.

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Novartis AG

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Merck & Co.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. AstraZeneca

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Sanofi

15.8.1. Company Overview

15.8.2. Product Offerings 

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Gilead Sciences, Inc

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. F. Hoffmann-La Roche

15.10.1. Company Overview 

15.10.2. Product Offerings 

15.10.3. Financial Performance 

15.10.4. Recent Initiatives 

Chapter 16. Research Methodology 

16.1. Primary Research 

16.2. Secondary Research 

16.3. Assumptions 

Chapter 17. Appendix 

17.1. About Us

17.2. Glossary of Terms